LAG3 and neoplasm: This combination regimen results in decreased levels of myeloid-derived suppressor cells (MDSC), splenic and intratumoral checkpoint-expressing T cells (PD-L1, LAG-3 and CTLA-4) and therefore positively modulates the tumor microenvironment.